Crossmark

Ultrasound responsive erythrocyte membrane-derived hybrid nanovesicles with controlled drug release for tumor therapy

Crossref DOI link: https://doi.org/10.1039/D1NR01916C

Published Online: 2021

Update policy: https://doi.org/10.1039/rsc_crossmark_policy

Authors

Wang, Dongdong https://orcid.org/0000-0001-5272-2011
Yao, Yuzhu https://orcid.org/0000-0001-8846-4472
Xiao, Yi https://orcid.org/0000-0002-2533-5259
Chen, Xue

Hu, Jun https://orcid.org/0000-0002-2568-9030
Yang, Xiangliang https://orcid.org/0000-0003-0683-8763
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81771978, 82072066, 81627901, 82073796)

National Key Research and Development Program of China (2018YFA0208903, 2020YFA0710700)
License Information

Accepted Manuscript valid from 2022-05-12
More Information

SIMILARITY CHECK

: This document is Similarity Check deposited

RELATED DATA

: Supplementary Information

IDENTIFIERS

: Dongdong Wang (ORCID)

: Yuzhu Yao (ORCID)

: Yi Xiao (ORCID)

: Jun Hu (ORCID)

: Xiangliang Yang (ORCID)

PEER REVIEW METHOD

: Single-blind

PUBLICATION HISTORY

: Received 26 March 2021; Accepted 9 May 2021; Accepted Manuscript published 12 May 2021; Advance Article published 31 May 2021; Version of Record published 10 June 2021